+1 (202) 780-3397
Pharmacogenetics Database of Lumiracoxib-induced DILI in healthy Thai population
36th International Conference on Immunology & Immunogenetics
August 13, 2021 | Webinar
Pantapat Chokpitakkul, Patompong Satapornpong, Ph.D
Shrewsbury International School Riverside, Bangkok, Thailand The division of general pharmacy practice, department of pharmaceutical care, College of Pharmacy, Rangsit University, Thailand (Corresponding author)
Scientific Tracks Abstracts : Immu Ca Rep
Abstract:
Lumiracoxib is a cyclooxygenase-2 inhibitor used mainly for symptomatic treatment of osteoarthritis and acute pain in patients. However, lumiracoxib is responsible for drug induced liver injury (DILI), an injury which has low incidence of occurrence but can cause serious life threatening outcomes. We found the genetic markers predictive of lumiracoxib- related hepatotoxicity in Europeans, consisting of HLADRB1* 15:01 (P=6.8x10-25, OR 7.5 and 95% CI = 5.0-11.3). Furthermore, HLA-DQA1*01:02 is also found associated with lumiracoxib-related hepatocellular injury with a 99.0% NPV and the highest sensitivity of 73.6% from genome-wide studies. Therefore, the distribution of pharmacogenetics markers were explored in the healthy Thai population. The aim of this study was to investigate the frequency of HLA-DRB1*15:01 and HLA-DQA1*01:02 associated with pharmacogenetics markers of lumiracoxib-induced DILI in the healthy Thai population. 200 participants in this study were recruited from an unrelated healthy Thai population. HLA class II alleles were genotyped using sequence-specific oligonucleotides. Our data revealed 41 alleles of the HLA- DRB1*15:01 (10.25%) and 98 alleles of the HLA-DQA1*01:02 (24.50%) in the Thai population. We founded the most allele frequencies are HLA-DRB1*15:02 (15.25%), -12:02 (14.25%), -15:01 (10.25%), -09:01 (8.75%), and -16:02 (7.50%). Furthermore, HLA-DQA1*01:01 (27.75%), -01:02 (24.50%), -03:02 (13.00%), -06:01 (10.25%), and -02:01 (4.50%) in Thais. Similarly in Europeans, there was also a high frequency of HLA- DRB1*15:01 (6.76%) and HLA-DQA1*01:02 (15.77%). To conclude, instead of completely withdrawing lumiracoxib from treatments, it is advisory to screen for the pharmacogenetics markers of HLA-DRB1*15:02 and HLA-DQA1*01:02 alleles in Thai patients for the purpose of avoiding DILI. Key Words: Pharmacogenetics database, DILI, Thai population, HLA-DQA1*01:02, HLA- DRB1*15:01
Biography:
Pantapat Chokpitakkul (Bob) is 17 years of age and studies at Shrewsbury International School, Bangkok. I am currently completing a literature review for publication and preparing an oral presentation for my preparations in applying to medicine in Thai and UK universities. I have an interest in precision medicine in particular, leading me to focus on this research.
PDF HTML